Single- Versus Dual-Time-Point Imaging for Transthyretin Cardiac Amyloid Using 99m Tc-Pyrophosphate
Journal of Nuclear Medicine Technology · 2025
DOI: 10.2967/jnmt.124.269395 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Nuclear Medicine Technology, 2025. Verfasst von Wesley Ng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria, Australia; wesley.ng@austin.org.au. Hauptthemen laut MEDLINE: Technetium Tc 99m Pyrophosphate, Amyloid Neuropathies, Familial, Amyloid, Prealbumin. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Nuclear medicine scintigraphy using 99mTc-pyrophosphate has proven valuable in the diagnosis of cardiac transthyretin amyloidosis in recent years. However, there is still confusion over the optimal imaging time points. The American Society of Nuclear Cardiology has recommended different imaging time points over the last decade. We aimed to determine whether single- or dual-time-point imaging is required for reporting purposes and which time point would be the most appropriate if a single time point was to be considered.
Methods
Cardiac amyloid scans using 99mTc-pyrophosphate acquired from 2017 to 2023 were retrieved from our Picture Archiving and Communications System. Scans with static views and SPECT/CT images of the chest for both imaging time points, at 1 h (early) and 3 h (delayed) after injection, were included. Each study was independently read by 3 nuclear medicine physicians. Original clinical reports using both imaging time points were used as a reference to calculate the accuracy of a single time point.
Results
In total, 70 patients were included in this study. Reports of cardiac amyloid studies using any single-time-point imaging were highly sensitive, accurate, and specific. There was agreement among all readers. Of the 140 datasets reported by each reader, 4 scans were classified as equivocal, requiring more imaging for confident reporting.
Conclusion
Single-time-point imaging showed an accuracy comparable to the dual-time-point imaging in diagnosing cardiac transthyretin amyloidosis. This was further validated by agreement among the 3 readers. Early time-point imaging is preferred, and additional delayed imaging can be acquired when the early result is equivocal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria, Australia; wesley.ng@austin.org.au.
- Discipline of Medical Imaging Science, University of Sydney, Sydney, New South Wales, Australia.
- Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria, Australia.
- Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
- School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.
- Brain and Mind Centre, University of Sydney; and.
Zitieren
APA
Ng, W., Pathmaraj, K., Kovaleva, N., Poon, A., Kench, P., Meikle, S., Scott, A., & Boktor, R. (2025). Single- Versus Dual-Time-Point Imaging for Transthyretin Cardiac Amyloid Using 99m Tc-Pyrophosphate. Journal of Nuclear Medicine Technology. https://doi.org/10.2967/jnmt.124.269395
Vancouver
Ng W, Pathmaraj K, Kovaleva N, Poon A, Kench P, Meikle S, et al. Single- Versus Dual-Time-Point Imaging for Transthyretin Cardiac Amyloid Using 99m Tc-Pyrophosphate. Journal of Nuclear Medicine Technology. 2025. doi:10.2967/jnmt.124.269395
BibTeX
@article{Ng2025,
author = {Ng, Wesley and Pathmaraj, Kunthi and Kovaleva, Natalia and Poon, Aurora and Kench, Peter and Meikle, Steven and Scott, Andrew and Boktor, Raef},
title = {Single- Versus Dual-Time-Point Imaging for Transthyretin Cardiac Amyloid Using 99m Tc-Pyrophosphate},
journal = {Journal of Nuclear Medicine Technology},
year = {2025},
doi = {10.2967/jnmt.124.269395}
}
EUVIMED